IMU

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Telit Cinterion Unveils High-Precision Global Navigation Satellite System IoT Module with Centimeter-Level Accuracy at Embedded World 2024

Retrieved on: 
Thursday, April 4, 2024
Satellite navigation, Swift, RTK, Embedded, Senior, Radio, Immunity, Wireless, Heart, Family, IMU, RTCM, GNSS, Surveying

IRVINE, Calif., April 4, 2024 /PRNewswire/ -- Telit Cinterion, an end-to-end IoT solutions enabler, announces the launch of its SE868K5-RTK module, a high-precision Global Navigation Satellite System (GNSS) receiver capable of centimeter-level accuracy.

Key Points: 
  • IRVINE, Calif., April 4, 2024 /PRNewswire/ -- Telit Cinterion, an end-to-end IoT solutions enabler, announces the launch of its SE868K5-RTK module, a high-precision Global Navigation Satellite System (GNSS) receiver capable of centimeter-level accuracy.
  • As the first GNSS module to provide centimeter-level accuracy in Telit Cinterion's extensive portfolio, the SE868K5-RTK is a multifrequency and multiconstellation positioning receiver module fortified by Real-Time Kinematics (RTK) capabilities that enhances positioning accuracy.
  • "The SE868K5-RTK demonstrates Telit Cinterion's unwavering commitment to delivering cutting-edge GNSS technology," said Marco Argenton, VP Product Management, IoT Modules at Telit Cinterion.
  • To learn more about the new SE868K5-RTK, visit Telit Cinterion at Embedded World April 9-11 in Hall 3 Stand 3-519.

SMOROBOT Launches Revolutionary Valor Series Intelligent Pool Cleaning Robots

Retrieved on: 
Thursday, March 28, 2024
Trident, Suction, FCC, Algorithm, CE, Intelligence, Laser, Travel, Artificial intelligence, RCM, Software, ROHS, Valor, Diving, REACH, Safety, IMU, Map, 3D printing

BEIJING, March 28, 2024 /PRNewswire/ -- On 28 March 2024, SMOROBOT officially unveiled the ValorTM series of intelligent robotic pool cleaners (hereinafter "Valor"), setting a new standard in automated pool cleaning and maintenance.

Key Points: 
  • BEIJING, March 28, 2024 /PRNewswire/ -- On 28 March 2024, SMOROBOT officially unveiled the ValorTM series of intelligent robotic pool cleaners (hereinafter "Valor"), setting a new standard in automated pool cleaning and maintenance.
  • Valor, a revolutionary intelligent cordless robotic pool cleaner from SMOROBOT, is forged from the accumulated experience and insights garnered from the Tank series.
  • With the launch of the Valor Series Robotic Pool Cleaner, SMOROBOT has significantly enhanced the user experience.
  • Valor now sets a new standard for functionality among pool cleaning robots worldwide, revolutionizing the industry with its groundbreaking capabilities.

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Retrieved on: 
Monday, March 11, 2024
Therapy, Amgen, Safety, CD19, Breast, ASX, Ovary, Patient, OASIS, IMU, Blinatumomab, Melanoma, Vaccine

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.

Key Points: 
  • Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.
  • The trial is titled: “A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors.” See https://clinicaltrials.gov/study/NCT06063317
    The combination arm of the study will see onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto® by Amgen which currently is specifically approved only for liquid blood cancers).
  • onCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blincyto® therapy alone and will represent a paradigm shift in solid tumour treatment.
  • OASIS is a dose escalation trial that will be conducted across multiple sites across the United States, with 52 patients proposed to take part in the trial.

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Retrieved on: 
Thursday, February 22, 2024
Allotransplantation, Skin cancer, Cholangiocarcinoma, Fast track (FDA), NHL, Melanoma, FDA, Pembrolizumab, CD19, Rupture, Lung, Epidemiology, Breast, Safety, Neoplasm, ASX, Bone marrow, Patient, RECIST, MAST, National library, IMU, Blinatumomab, DLBCL, Cancer, BTC, Vaccine

Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.

Key Points: 
  • Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.
  • Notably, in our Phase 1 MAST CF33 oncolytic virus trial, we’ve seen encouraging response rates during dose escalation, including one complete response in a patient with cholangiocarcinoma, and two partial responses in melanoma as we continue to dose escalate with no safety issues.
  • Importantly, two out of three of these responses were achieved with CF33 monotherapy.
  • onCARlytics uses an antigen/target-armed CF33, followed by treatment with a CD19 targeting therapy directed against that antigen or target.

POLARIS ANNOUNCES 2025 SNOWMOBILE LINEUP FEATURING NEW TECHNOLOGY, MODEL UPGRADES

Retrieved on: 
Tuesday, March 5, 2024
Titan, Matryx, RIDE, Love, Bluetooth, SP, News, Beauty, RMK, Inertial measurement unit, The Transformers (TV series), TITAN, Snowmobile, Nack, Feedback, Metric system, 9R, GPS, Acceleration, Inertial frame of reference, Snow, IMU, Polaris Inc., Wi-Fi, VR1, XCR, Display, Amusement park

MINNEAPOLIS, March 5, 2024 /PRNewswire/ -- Polaris Inc. (NYSE: PII) is again redefining what is possible on snow with the launch of its 2025 Snowmobiles and Timbersled lineup. Polaris' 2025 snow lineup offers the latest in industry-leading technology and engineered upgrades that enhance the riding experience, from introducing its patented DYNAMIX suspension technology that offers riders more comfort and control, to designing a lighter RMK lineup that gives mountain riders even more control, to launching new models with the RMK SP and 650 Titan Adventure widetrack and expanding the availability of the customer-favorite Patriot 9R engine. In addition, Polaris provides riders with the opportunity to build their dream snowmobiles through SnowCheck, the industry's most comprehensive customization order program for customers, which is available through March 27, 2024.

Key Points: 
  • "With our 2025 snowmobile lineup, we are introducing new features, technology or upgrades across nearly every one of our snow segments.
  • Polaris is once again setting new standards by bringing its patented DYNAMIX suspension to snow on the 2025 INDY VR1 via SnowCheck exclusive.
  • The Polaris Rocky Mountain King (RMK) redefined the standards for deep snow performance, and Polaris is doing so again with model year 2025.
  • In addition to technology advancements, the Polaris Snow model year 2025 lineup features more than 20 quality improvements to help deliver the best riding experience on snow.

Scientific Systems Develops Non-GPS Navigation for GPS-Denied Environments

Retrieved on: 
Wednesday, February 21, 2024
Weapon, Senior, Aircraft, Algorithm, Intelligence, UAS, BBC, GPS, EO, IMU, Software, Satellite navigation device

WOBURN, Mass., Feb. 21, 2024 /PRNewswire/ -- Scientific Systems, an industry leader in advanced artificial intelligence for defense applications, announced today that it is continuing development of ImageNav™, the company's non-GPS, image-based, precision navigation software. The company has recently extended and demonstrated its image-based solution during flight operations ranging from 25,000 feet down to 200 feet. ImageNav has been developed for over a decade with funding totaling more than $45 million.

Key Points: 
  • For many air vehicle flights, the military relies on the Global Positioning System (GPS) for navigation, risking exposure to electronic jamming in contested environments.
  • ImageNav provides accurate navigation, without GPS, for a range of systems, including weapons, aircraft, and uncrewed aircraft systems (UAS).
  • "ImageNav is an innovative, compact solution that helps air vehicles generate accurate position fixes in the most challenging environments," said Tom Frost, Senior VP of the Products Division at Scientific Systems.
  • Scientific Systems has multiple efforts underway to integrate ImageNav onto GPS-guided munitions and UASs, enabling them to operate in GPS-denied environments.

BOSE ANNOUNCES NEW ULTRA OPEN EARBUDS

Retrieved on: 
Thursday, February 15, 2024
Smoke, Motion, Inertial measurement unit, Skin, Life, IPX4, Ear, Sound, Android, Walking, Jewellery, X11 color names, Fast Pair, Inertial frame of reference, IMU, Music, Water, Cassette tape

FRAMINGHAM, Mass. , Feb. 15, 2024 /PRNewswire/ -- Today, Bose introduces a breakthrough audio wearable that lets you hear the world around you while still enjoying your music uninterrupted. The new Bose Ultra Open Earbuds feature an innovative cuff-shaped design that looks as good as it sounds. They provide amazing comfort for all-day wear without making you choose between immersive audio and awareness. Pause for nothing and hear everything.  

Key Points: 
  • The new Bose Ultra Open Earbuds feature an innovative cuff-shaped design that looks as good as it sounds.
  • The Ultra Open Earbuds are available starting today for $299 on Bose.com and through select resellers.
  • The Bose Ultra Open Earbuds were made to be worn throughout the day.
  • Bose Ultra Open Earbuds also work with Bose SimpleSync technology, allowing you to pair them with select Bose smart soundbars and speakers for a personal listening experience.

BOSE ANNOUNCES NEW ULTRA OPEN EARBUDS

Retrieved on: 
Thursday, February 15, 2024
Smoke, Motion, Inertial measurement unit, Skin, Life, IPX4, Ear, Sound, Android, Walking, Jewellery, X11 color names, Fast Pair, Inertial frame of reference, IMU, Music, Water, Cassette tape

FRAMINGHAM, Mass., Feb. 15, 2024 /PRNewswire/ -- Today, Bose introduces a breakthrough audio wearable that lets you hear the world around you while still enjoying your music uninterrupted. The new Bose Ultra Open Earbuds feature an innovative cuff-shaped design that looks as good as it sounds. They provide amazing comfort for all-day wear without making you choose between immersive audio and awareness. Pause for nothing and hear everything.  

Key Points: 
  • The new Bose Ultra Open Earbuds feature an innovative cuff-shaped design that looks as good as it sounds.
  • The Ultra Open Earbuds are available starting today for £299 on Bose.com and through select resellers.
  • The Bose Ultra Open Earbuds do just that.
  • Bose Ultra Open Earbuds also work with Bose SimpleSync technology, allowing you to pair them with select Bose smart soundbars and speakers for a personal listening experience.